Glutamine has the potentials of immunomodulation and adjustment of protein metabolism. The primary objective of this study is to evaluate the efficacy of glutamine on sarcopenia in gastric adenocarcinoma patients undergoing gastrectomy. The secondary endpoints, including the physical activity, weight loss, and nutritional profiles, will be evaluated among these patients.
This will be a double-blind, randomized, and placebo-controlled study. At least 80 evaluable patients who are scheduled for gastrectomy for gastric adenocarcinoma cancer will be randomly assigned to the control or treatment group. Each group will have at least 40 patients. The CT scan will be evaluated before surgery and on postoperative day (POD) 90. Moreover, the patient will wear the smart watch to record daily walking steps. Laboratory data will be check before gastrectomy and on POD 90.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
120
10 g glutamine +5 g Maltodextrin for 28 days after surgery with tolerable oral intake or enteral feeding
Maltodextrin
National Taiwan University Hospital
Taipei, Taiwan
RECRUITINGChange of area of psoas muscle
area od psoas muscle on the CT scan
Time frame: 84 days after gastrectomy
Walking steps
the average daily walking steps recorded by the wearable devices
Time frame: 28,56, and 84 days after gastrectomy
body weight
body weight
Time frame: 84 days after gastrectomy
Change of serum albumin value
Time frame: 84 days after gastrectomy
Change in white blood cells counts
Time frame: 84 days after gastrectomy
Change in lymphocyte cells counts
Time frame: 84 days after gastrectomy
Change of serum pre-albumin value
Time frame: 84 days after gastrectomy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.